About Moderna, Inc
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., and Recipharm for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Address: 200 Technology Square, Cambridge, MA, United States, 02139
Moderna, Inc News and around…
Latest news about Moderna, Inc (MRNA) common stock and company :
The U.S. Food and Drug Administration will act as soon as possible on Moderna Inc's application seeking approval of its COVID-19 vaccine for children under age 5, the agency's chief told lawmakers on Thursday. "There's no delay in Moderna's application," FDA Commissioner Robert Califf told a U.S. House Agriculture subcommittee, adding the agency was preparing for public hearings on the company's bid "as quickly as possible."
InvestorPlace - Stock Market News, Stock Advice & Trading Tips History has repeatedly shown that steep corrections are the perfect time to shop for undervalued stocks. These are among the most undervalued stocks to invest in now. DELL, GPRO, HON, FB, MU, MRNA, and STX can make great investments. The post The 7 Most Undervalued Stocks to Buy After the Sell-Off appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Off and on the price chart these three blue-chip tech stocks look great to buy following earnings beats and attractive price charts. The post 3 Blue-Chip Tech Stocks to Buy Now appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
CAMBRIDGE, MA / ACCESSWIRE / May 18, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the UBS 2022 Global Healthcare Conference on Tuesday, May 24th at 9:15 a.m. ET.
NASDAQ has given Dentsply Sirona Inc. notice that its failure to file its latest quarterly report with the Securities and Exchange Commission violates NASDAQ listing rules and could result in delisting.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we ...
In a post-COVID world, there are fewer question marks about Pfizer than there are about Moderna.
These two stocks are posting strong results despite the broader market sell-off.
Just hours after the official U.S. COVID-19 death toll passed the one million mark, the White House is planning to hold its first coronavirus briefing in six weeks and the first to be led by new COVID response coordinator Dr. Ashish Jha.
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus FDA Gives Green Signal To ...
Moderna (MRNA) stock rises more than 4% on May 17. The COVID-19 vaccine-maker attracts investors on the back of a promising update from one of its competitors.
Pfizer (PFE) and partner BioNTech gets authorization for emergency use of booster dose of its COVID-19 vaccine, Comirnaty, in children aged between 5 years and 11 years.
Vertex's (VRTX) cystic franchise sales continue to grow. Vertex has a broad clinical non-CF pipeline, which is progressing rapidly.
But it's not the stock that investors should be worried about.
CNBC Toyota Looks To Develop Hydrogen Mobility In Europe Toyota Motor Corp (NYSE: TM) said Its Europe business, Air Liquide, ...
Moderna Inc’s(NASDAQ: MRNA) chairman comes forward with a determined defense of the board’s executive hiring ...
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
It's entering a new market -- one that has authorized its vaccine.
Moderna’s chair has launched an unflinching defence of the board’s executive hiring process after its new chief financial officer stepped down last week following just one day in the job. Noubar Afeyan dismissed suggestions the board could have done anything differently, insisting it had asked all the right questions but was not told about an internal investigation into financial reporting at Jorge Gomez’s former employer because of legal constraints. Afeyan said the executive search company contracted by Moderna, the biotech company behind one of the leading Covid-19 vaccines, was also blameless because it was unaware of the probe by dental equipment maker Dentsply Sirona, which was disclosed last week.
Vaccine stocks Pfizer and BioNTech rose moderately Tuesday after the Food and Drug Administration signed off on Covid boosters for children.
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 105.44% on an annualized basis producing an average annual ...
Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed ...
By Liz Moyer
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
The company earns an Emergency Use Authorization from a well-off Middle Eastern country.
Is Moderna stock a buy after beating first-quarter Covid vaccine sales expectations? Is MRNA stock a buy right now?
US crude oil futures traded lower, dropping around 0.5% on Monday. Investors, meanwhile, focused on some notable insider trades. When ...
CNBC Volkswagen CEO Shares Ambitious EV Ambitions For US Market Volkswagen AG (OTC: VWAGY) looks to re-launch the Scout as a ...
Moderna Inc(NASDAQ: MRNA)released new detailsabout the abrupt departure of Chief Financial Officer Jorge Gomez, saying ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips These undervalued blue-chip stocks can generate sturdy gains in the long term, mitigating inflation and higher interest rate risks. The post 7 Undervalued Blue-Chip Stocks to Buy Now appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”